| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms AMB 303, AMB303 | 
| Target | 
| Action antagonists, inhibitors | 
| Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | South Korea  | 29 Apr 2025 | |
| Triple Negative Breast Cancer | Preclinical | South Korea  | 29 Apr 2025 | |
| Solid tumor | Preclinical | South Korea  | 01 Nov 2024 | 






